Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00149630 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenetics of Disulfiram for Cocaine
A Phase 2 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT00149630 is a Phase 2 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 93 participants.
The verdict
NCT00149630, a Phase 2 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
Previous research has shown that disulfiram, a medication sometimes used for treating alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone treatment. By blocking the enzyme dopamine beta hydroxylase (DBH), disulfiram increases levels of dopamine and produces an unpleasant sense of hyperstimulation and discomfort in cocaine users. This study will evaluate the effectiveness of disulfiram in preventing drug relapse among cocaine and opiate addicts with varying inherited levels of DBH.
Interventions
- DRUG Methadone
- BEHAVIORAL CBT
- DRUG Disulfiram
- OTHER Lactose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00149630
The ClinicalTrials.gov registry entry for NCT00149630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Methadone is the first listed.
NCT00149630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00149630 about?
NCT00149630 is a clinical study titled "Pharmacogenetics of Disulfiram for Cocaine". Previous research has shown that disulfiram, a medication sometimes used for treating alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone treatment. By blocking the enzyme dopamine beta hydroxylase (DBH), disulfiram increases levels of dopamine and produces an unpl...
What is the current status of trial NCT00149630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2005-01. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00149630?
The interventions under investigation include: Methadone (DRUG), CBT (BEHAVIORAL), Disulfiram (DRUG), Lactose (OTHER).
Who is sponsoring clinical trial NCT00149630?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.